207 related articles for article (PubMed ID: 32299423)
1. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.
Kim L; Boxall N; George A; Burling K; Acher P; Aning J; McCracken S; Page T; Gnanapragasam VJ
BMC Med; 2020 Apr; 18(1):95. PubMed ID: 32299423
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
[TBL] [Abstract][Full Text] [Related]
4. Performance of prostate health index and PSA density in a diverse biopsy-naïve cohort with mpMRI for detecting significant prostate cancer.
Carbunaru S; Stinson J; Babajide R; Hollowell CMP; Yang X; Sekosan M; Ferrer K; Kajdacsy-Balla A; Abelleira J; Ruden M; King-Lee P; Dalton DP; Casalino DD; Kittles RA; Gann PH; Schaeffer EM; Murphy AB
BJUI Compass; 2021 Nov; 2(6):370-376. PubMed ID: 35474697
[TBL] [Abstract][Full Text] [Related]
5. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.
Gnanapragasam VJ; Burling K; George A; Stearn S; Warren A; Barrett T; Koo B; Gallagher FA; Doble A; Kastner C; Parker RA
Sci Rep; 2016 Oct; 6():35364. PubMed ID: 27748407
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer.
Panebianco V; Valerio MC; Giuliani A; Pecoraro M; Ceravolo I; Barchetti G; Catalano C; Padhani AR
Eur Urol Oncol; 2018 Aug; 1(3):208-214. PubMed ID: 31102623
[TBL] [Abstract][Full Text] [Related]
7. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract][Full Text] [Related]
8. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Agostino J; Macura KJ; Carter HB; Schaeffer EM; Partin AW; Sokoll LJ; Ross AE
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):228-233. PubMed ID: 28117387
[TBL] [Abstract][Full Text] [Related]
9. Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators.
Falagario UG; Martini A; Wajswol E; Treacy PJ; Ratnani P; Jambor I; Anastos H; Lewis S; Haines K; Cormio L; Carrieri G; Rastinehad AR; Wiklund P; Tewari A
Eur Urol Oncol; 2020 Oct; 3(5):700-704. PubMed ID: 31548130
[TBL] [Abstract][Full Text] [Related]
10. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
Faria R; Soares MO; Spackman E; Ahmed HU; Brown LC; Kaplan R; Emberton M; Sculpher MJ
Eur Urol; 2018 Jan; 73(1):23-30. PubMed ID: 28935163
[TBL] [Abstract][Full Text] [Related]
11. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
Siddiqui MR; Li EV; Kumar SKSR; Busza A; Lin JS; Mahenthiran AK; Aguiar JA; Shah PV; Ansbro B; Rich JM; Moataz SAS; Keeter MK; Mai Q; Mi X; Tosoian JJ; Schaeffer EM; Patel HD; Ross AE
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):588-595. PubMed ID: 36973367
[TBL] [Abstract][Full Text] [Related]
12. A prospective study investigating the impact of multiparametric MRI in biopsy-naïve patients with clinically suspected prostate cancer: The PROKOMB study.
Baur ADJ; Henkel T; Johannsen M; Speck T; Weißbach L; Hamm B; König F
Contemp Clin Trials; 2017 May; 56():46-51. PubMed ID: 28279782
[TBL] [Abstract][Full Text] [Related]
13. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
[TBL] [Abstract][Full Text] [Related]
14. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric MRI in men with clinical suspicion of prostate cancer undergoing repeat biopsy: a prospective comparison with clinical findings and histopathology.
Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
Acta Radiol; 2018 Mar; 59(3):371-380. PubMed ID: 28679325
[TBL] [Abstract][Full Text] [Related]
16. Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer.
Agnello L; Vidali M; Salvaggio G; Agnello F; Lo Sasso B; Gambino CM; Ciaccio M
Clin Biochem; 2024 May; 127-128():110759. PubMed ID: 38583655
[TBL] [Abstract][Full Text] [Related]
17. Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification.
de la Calle CM; Jing Y; Mamawala MM; Landis P; Macura KJ; Trock BJ; Epstein JI; Sokoll LJ; Pavlovich CP
Urol Oncol; 2023 Nov; 41(11):455.e1-455.e6. PubMed ID: 37722985
[TBL] [Abstract][Full Text] [Related]
18. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
[TBL] [Abstract][Full Text] [Related]
19. Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
Deniffel D; Abraham N; Namdar K; Dong X; Salinas E; Milot L; Khalvati F; Haider MA
Eur Radiol; 2020 Dec; 30(12):6867-6876. PubMed ID: 32591889
[TBL] [Abstract][Full Text] [Related]
20. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2015 Feb; 13(1):e27-30. PubMed ID: 25081324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
